Caitlin May, PhD, postdoctoral research fellowship at Eli Lilly and Company, discusses olaratumab's (Lartruvo) demonstrating anti-tumor activity in models of pediatric bone and soft-tissue sarcoma.
Caitlin May, MD
Advertisement
Articles by Caitlin May, MD
Advertisement
Latest Updated Articles
Dr. May on Olaratumab Activity in Pediatric Bone and Soft Tissue SarcomaPublished: January 21st 2017 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
The OncFive: Top Oncology Articles for the Week of 1/25
3
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
4
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
5